Alpa Laboratories Limited IPO (Alpa IPO) Detail

Jul 12, 2007 - Jul 17, 2007

Alpa Laboratories Limited is in the business of manufacturing of pharmaceutical formulations. Alpa manufacture a range of products such as ethical drugs, generic drugs, over the counter drugs (OTC) and veterinary products in various dosage forms. It also manufacture formulations for a number of other pharmaceutical companies of national and international repute such as Cipla, Zydus Cadila, Lupin, Glenmark, Genom Biotech, Jenburkt, etc. (under their own brands).

Alpa Laboratories manufacture various dosage forms which include injectables (vials / ampoules both liquid and dry), tablets, capsules, eye / ear drops, ointment and creams and dry syrups.

Objects of the Issue

The objects of the Issue are to achieve the benefits of listing on the Stock Exchanges & to raise capital for
1. Setting up a new plant at Pigdamber, Indore for increasing our production & testing capacities;
2. Meeting Margin money working capital requirements.

Alpa IPO Details

IPO Date Jul 12, 2007 to Jul 17, 2007
Listing Date Monday, August 6, 2007
Face Value ₹10 per share
Price ₹62 to ₹68 per share
Lot Size 100 Shares
Issue Size9,500,000 shares of ₹10
(aggregating up to ₹64.60 Cr)
Issue Type Book Built Issue IPO
Listing At BSE, NSE

Alpa IPO Lot Size

The Alpa IPO lot size is 100 shares. A retail-individual investor can apply for up to 29 lots (2900 shares or ₹197,200).

Application Lots Shares Amount
Retail (Min) 1 100 ₹6,800
Retail (Max) 29 2900 ₹197,200

Alpa IPO Subscription Status (Bidding Detail)

The Alpa IPO is subscribed 1.11 times on Jul 17, 2007 5:00:00 PM. The public issue subscribed 2.14 times in the retail category, 0.18 times in the QIB category, and 1.99 times in the NII category. Check Day by Day Subscription Details (Live Status)

CategorySubscription (times)

Alpa IPO Prospectus

Alpa IPO Rating

Rating:Rated 3.4 stars
Vote Here ...

Alpa IPO Listing Date

Listing Date Monday, August 6, 2007
BSE Script Code 532878
Listing In B1 Group of Securities
ISIN INE385I01010
IPO Price ₹68 per share
Face Value ₹10 per share

Listing Day Trading Information

IPO Price
Last Trade

Company Contact Information

Alpa Laboratories Limited
Alpa Laboratories Limited,
33/2, Pigdamber, A.B. Road, Rau,
District Indore - 453446, Madhya Pradesh, India
Phone: +91-0731-4020440

Alpa IPO Registrar

Bigshare Services Pvt Ltd

Phone: +91-22-6263 8200

Alpa IPO Review

Alpa IPO Recommendation Summary

Review By Subscribe Neutral Avoid
Brokers 0 0 1
Members 0 0 0

Read All Reviews Post Your Review Manage Reviews

IPO Broker Recommendations

  • S P Tulsian - Avoid


Alpa IPO is a main-board IPO of 9,500,000 equity shares of the face value of ₹10 aggregating up to ₹64.60 Crores. The issue is priced at ₹62 to ₹68 per share. The minimum order quantity is 100 Shares.

The IPO opens on Jul 12, 2007, and closes on Jul 17, 2007.

Bigshare Services Pvt Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.

The Alpa IPO opens on Jul 12, 2007 and closes on Jul 17, 2007.

Alpa IPO lot size is 100 Shares and the minimum order quantity is .

You can apply in Alpa IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. Read more detail about apply IPO online through Zerodha, Upstox, 5Paisa, Edelweiss, ICICI Bank, HDFC Bank and SBI Bank.

The finalization of Basis of Allotment for Alpa IPO will be done on [.], and the allotted shares will be credited to your demat account by [.]. Check the Alpa IPO allotment status.

The Alpa IPO listing date is on Monday, August 6, 2007.
Open an Instant Account with Zerodha

Alpa IPO Message Board

Ranked Members of Forum  Ranked Members | Most Liked Members



38. Sonu ipo |   Link |Aug 17, 2007 1:06:34 PM
hello everybody

wat to do with shares of alpa lab and ivr prime....should sell or hold.........please suggest?

37. market expert |   Link |Aug 5, 2007 8:16:30 PM
it will list around 68 - 70 adn will go down in seconds to
60 - 55. so u will be in loss on the same day .

sell at the loss of 5 rs .....below that hold or buy at the level of 52 - 55 and than sell to balance the both at the level of 60 .

global cues r not pretty good . so market will not make a good movement to upwards but it can go down instead .

36. vikas sharma |   Link |Aug 5, 2007 4:21:10 PM
I Got 200 Shares of alpa lab what to do any one
can say about expected profit or loss or on which rate
to sell ?
35. uraheja |   Link |Aug 5, 2007 3:23:23 PM
listing tomorrow ...
34. kishore |   Link |Aug 5, 2007 8:28:24 AM
alpa lab very bad , be cautious
33. raju |   Link |Aug 4, 2007 8:47:31 PM
sell sell sell sell 55 to 59
32. pramod |   Link |Aug 4, 2007 3:57:04 PM
i Got 1000 Shares of alpa lab what to do any one
can say about expected profit or loss or on which rate
to sell?
31. Murthy |   Link |Aug 3, 2007 12:45:56 PM
what is the expected list price?????
30. KINJAL |   Link |Aug 2, 2007 9:15:40 PM
29. Pramod |   Link |Aug 1, 2007 6:12:28 PM
I Get 1000 Share of Alpa Lab
What todo and on which price it will be listed ?
28. raja |   Link |Aug 1, 2007 4:20:57 PM
when is alpa listing date?????
i got 1000shares alloted....
huff i dono wat to do..
pls guys help me.....
27. SANDEEP |   Link |Aug 1, 2007 11:17:25 AM
26. elan |   Link |Jul 30, 2007 6:17:43 PM
when will be the listing date for alpa?
25. tanushri |   Link |Jul 21, 2007 6:11:08 PM

If cannot take risk, then go for stop payment of the cheque.
24. Vikram |   Link |Jul 16, 2007 3:36:20 AM
Financial Express Report

Alpa Laboratories is in the business of manufacturing pharmaceutical formulations, ethical drugs, generic drugs, over the counter (OTC) drugs and veterinary products in various dosages and forms. Apart from catering to formidable domestic players like Cipla, Zydus Cadila, Lupin, and Glenmark, the company also exports to countries like Iran, Iraq, Nigeria and Sri Lanka. It has categorised its business into four major divisions: generics, veterinary, exports, and contract manufacturing ( which includes outsourcing of bulk drugs, drug intermediaries, and formulations)

The company intends to put up a capital of around Rs 64.9 crore at the higher end of the price band. It intends to set up a new plant at Pigdamber, Indore to increase its production and testing capacities.

The plant will take into account the manufacturing of liquid injectibles, dry powder injectibles, tablets and capsules, ointments and house a new analytical laboratory. The company, with regard to production of liquid injections, intends to almost treble its capacity to 6,50,000 units from 1,50,000 with the current capacity utilisation of almost 97%.

It also plans to increase the production of dry powder injections to 3,25,000 ( from 125000), ampoules to 3,00,000 ( from 65,000), tablets to 15,00,000 ( from 1,50,000), capsules to 6,00,000(from 1,00,000), creams to 80,000 (from 40,000), ear and eye drops to 80, 000 (from 40,000) and dry syrups to 40,000 ( from 12,000). The pharmaceutical company aims to almost double its capacity of the above mentioned products, while the current capacity utilisation for these products being around 85-90%.

Investonomics :
The pharmaceutical industry is growing at a CAGR of 13.7% per annum. It is eliciting investments both from MNCs and domestic players equally, which have more emphasis on bio-tech and aspects of brand development. According to the Boston Consulting group, contract manufacturing market in India would touch $900 million by 2010 and contract manufacturing in the Indian pharmaceutical industry is estimated to grow at an exponential rate. Hence, a company like Alpa Laboratories stands a good chance of leveraging this trend.

But a lot depends upon the projection execution capabilities of the company. It’s claim to treble its liquid injections capacity and almost double the capacities of various other products like dry powder injections, tablets, capsules, and dry syrups in a span of two years is crucial and calls for attention. The reason being, that these expansions may impact the short-term operating costs of the company and in turn affect earnings.

What is more significant is the company’s ability to manage the sales of the various products. In addition to this, the presence of promoters in the pharmaceutical business, under the name Alpa Labs India, which may result in the conflict of interest between Alpa Laboratories and Alpa Labs India.

Valuation :
On the valuation front, considering the post-issue equity on a fully diluted basis, the company quotes a P/E of around 20.88(x) and 22.90(x) at the lower and upper end of the price band.

An immediate comparison with industry peers like Syncom Fomulations, Parental Drugs, and Venus Remedies which quote a P/E of around 4.4(x), 6.4(x) and 15.4(x) respectively shows that the scrip is high-priced. Investors must take into account these facts before taking the plunge.
23. Lokesh Roy |   Link |Jul 14, 2007 5:14:59 PM
Avoid this one ....
Try other, lots of ipo's are there on the pipe line........
22. Thilagar From Tamil Nadu |   Link |Jul 14, 2007 11:19:46 AM
Any Body Tell Me Alpa IPO is Good. I am Not a Invester & Short Term Trater Just Sell on List Day. Its Good ?.
21. INVESTOR |   Link |Jul 13, 2007 8:17:32 PM
this is average issue, not much intrest seen, one can go
for small application as may get firm allotement, due to aggresivly priced one can earn 7-8 rs , which may not be
great return. risk is higher.
20. umesh |   Link |Jul 13, 2007 6:30:30 PM
pls.anybody tell me can i invest in alpa.
19. tanushree |   Link |Jul 13, 2007 12:03:49 AM
Dont invest in this Ipo. Alpa Laborataries is just taking advantage of the bull market.Fair price would have been around 48 they have priced quite aggresively. stay away from this bad ipo